Use: As an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. Usual Pediatric Dose for Diabetes Type 2: 10 years and older: Extended-release: 2 mg subcutaneously once every 7 days (weekly) ...
(2 mg weekly), no significant changes in acetaminophen auc were observed compared to the control period. acetaminophen cmax decreased by 16% (fasting) and 5% (fed) and tmax was increased from approximately 1 hour in the control period to 1.4 hours (fasting) and 1.3 hours (fed). the ...
The clinical development programme DURATION showed that exenatide 2 mg once weekly more markedly reduces glycated haemoglobin (HbA(1c)), with a similar weight loss but a better digestive tolerance profile (less nausea and vomiting after treatment initiation), compared with the twice daily 10 microg...
BYDUREON is an investigational medication for type 2 diabetes. "If approved, we believe BYDUREON will be an important new option for type 2 diabetes patients, as the first once-weekly treatment available in the U.S.," said Christian Weyer, M.D., senior vice president, research and ...
(GLP-1) receptor agonist exenatide,slow release in the body to play long-term hypoglycemic effect by themicrosphere technique, it can be administered once-weekly, 2 mg each time.The patient can be dosed at any time of the day, regardless of meal or not.Bydureon® have been proved by ...
阿斯利康计划今年晚些时候在美国市场正式推出Bydureon Pen。 编译自:US FDA approves Bydureon® Pen (exenatide extended-release for injectable suspension) for once-weekly treatment of adults with type 2 diabetes. AstraZeneca Press. Monday, 3 March 2014...